重组人干扰素α2b辅助治疗新生儿肺炎的疗效观察

Efficacy of recombinant human interferonα2b in the adjuvant treatment of neonatal pneumonia

目的观察重组人干扰素α2b辅助治疗新生儿肺炎的疗效。方法选取2020年1月至2022年1月灵璧县人民医院收治诊断为新生儿肺炎患儿60例为研究对象,采用随机对照研究,按照随机数字表法分为研究组、对照组各30例,对照组采用常规治疗,研究组在对照组基础上联合重组人干扰素α2b治疗。两组治疗7 d后,比较两组临床症状缓解时间、总有效率及炎性因子水平。结果治疗前,研究组与对照组患儿一般资料比较,差异均无统计学意义(均P>0.05)。治疗后7 d,研究组患儿体温恢复、啰音消失、咳嗽消失、气促消失时间分别为(4.03±1.27)d、(5.13±1.72)d、(4.96±1.64)d、(5.45±1.52)d,均短于对照组的(5.13±1.52)d、(6.73±1.85)d、(6.73±1.82)d、(6.82±1.74)d,差异均有统计学意义(t=3.04、3.46、3.95、3.24,均P<0.05)。研究组总有效率[93.3%(28/30)]高于对照组[80.0%(24/30)],临床疗效好于对照组(Z=2.40,P=0.016)。研究组超敏C反应蛋白、降钙素原、白细胞介素6、血清淀粉样蛋白A分别为(2.96±0.84)mg/L、(0.72±0.33)μg/L、(6.25±2.18)ng/L、(3.48±1.13)mg/L,均低于对照组的(4.02±1.53)mg/L、(1.16±0.47)μg/L、(8.04±2.06)ng/L、(6.42±2.03)mg/L,差异均有统计学意义(t=3.32、4.19、3.26、6.93,均P<0.05)。结论重组人干扰素α2b辅助治疗新生儿肺炎可缩短临床症状缓解时间,降低炎性因子水平,提高疗效。

Objective To investigate the efficacy of recombinant human interferonα2b in the adjuvant treatment of neonatal pneumonia.Methods A total of 60 children with neonatal pneumonia who received treatment in Lingbi County People's Hospital from January 2020 to January 2022 were included in this study.They were randomly divided into study and control groups(n=30/group).The control group was treated with conventional therapy and the study group was treated with recombinant human interferonα2b and conventional therapy.All children were treated for 7 days.The time to clinical symptom remission,total response rate,and inflammatory factor levels were compared between the two groups.Results Before treatment,there were no significant differences in general data between the study and control groups(all P>0.05).After treatment,the time to body temperature recovery,rale disappearance,cough disappearance,and shortness of breath disappearance in the study group were(4.03±1.27)days,(5.13±1.72)days,(4.96±1.64)days,and(5.45±1.52)days,respectively,which were significantly shorter than(5.13±1.52)days,(6.73±1.85)days,(6.73±1.82)days,and(6.82±1.74)days,respectively in the control group(t=3.04,3.46,3.95,3.24,all P<0.05).The total response rate in the study group was 93.3%(28/30),which was significantly higher than 80.0%(24/30)in the control group,and clinical efficacy was better in the study group than that in the control group(Z=2.40,P=0.016).High-sensitivity C-reactive protein,procalcitonin,interleukin-6,and serum amyloid A in the study group were(2.96±0.84)mg/L,(0.72±0.33)μg/L,(6.25±2.18)mg/L,and(3.48±1.13)mg/L,respectively,which were significantly lower than(4.02±1.53)mg/L,(1.16±0.47)μg/L,(8.04±2.06)ng/L,and(6.42±2.03)mg/L,respectively in the control group(t=3.32,4.19,3.26,6.93,all P<0.05).Conclusion Recombinant human interferonα2b for the adjuvant treatment of neonatal pneumonia can shorten the time to clinical symptom remission,decrease inflammatory factor levels,and improve clinical efficacy.